在患有血液恶性瘤的患者中,对Venetoclax与Voriconazole同时使用的人口药理学研究
Jing Yang1,2,3, Haoran Wang1, Dongmei Liu1
1Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, People's Republic of China.
同时使用voriconazole显著增加了血液恶性瘤患者的venetoclax暴露. 这种药物相互作用需要仔细的治疗药物监测,以确保安全有效的venetoclax治疗.
科学领域:
- 药理动力学 药理动力学
- 药物相互作用 药物相互作用
- 血液学恶性瘤 血液学恶性瘤
背景情况:
- 维内托克拉克斯是一种BCL-2抑制剂,用于血液恶性瘤.
- 与沃里康纳等CYP3A抑制剂同时使用可能会导致显著的药物相互作用 (DDI).
- 由于DDI而增加的venetoclax暴露可能导致不良事件.
研究的目的:
- 为venetoclax.开发一个人群药理动力学 (PopPK) 模型.
- 在与voriconazole联合使用时,描述venetoclax PK.
- 为了优化venetoclax在存在voriconazole时的剂量方案.
主要方法:
- 使用30名患者的数据开发了一个PopPK模型.
- 外部验证是使用43名患者的数据进行的.
- 使用蒙特卡洛模拟来评估剂量策略.
主要成果:
- 一个两部分线性模型描述了venetoclax度.
- 专是影响venetoclax清除的显著共同变量.
- 沃里科纳显著增加了venetoclax的暴露,在两周内观察到积累.
结论:
- 同时服用伏利可纳会增加威尼托克拉克斯的暴露.
- 观察到的DDI突显了治疗药物监测的必要性.
- 在结合这些药物时,调整剂量或密切监测至关重要.
更多相关视频
12:29Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus
Published on: April 19, 2017
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
相关概念视频
Analysis of Population Pharmacokinetic Data
Factors Affecting Renal Clearance: Drug's Physicochemical Properties and Plasma Levels
One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Nonlinear Pharmacokinetics: Overview
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Pharmacokinetics: Overview
